Q1 FY27 results: revenue up 17%, PAT up 7%; promoter warrant conversion of 7.86L shares

Related-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹100.00

prior close

₹98.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+4.9% vs market

Pharmaceuticals peers, median of 166sector-0.4%+5.4% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

+6.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.1+4.9-0.4+5.4

Next day

+4.0+0.2+3.8-0.5+4.4

+2.0+0.6+1.4-0.6+2.6

+1.0-0.0+1.0-1.4+2.4

+0.0+0.5-0.5-0.9+0.9

+1.0+0.8+0.2-0.4+1.4

+0.0+0.6-0.6-0.9+0.9

15d

+5.5+1.3+4.2+0.0+5.5

+8.0-1.4+9.4-0.1+8.1

+34.5-0.6+35.0-2.8+37.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved un-audited Q1 FY27 results. Revenue from operations rose 17% to Rs. 27.96 crores (vs Rs. 23.81 cr YoY). Net profit grew about 7% to Rs. 1.11 crores (vs Rs. 1.04 cr YoY). Also allotted 7,86,690 equity shares to promoters on conversion of warrants at Rs. 89 each, raising Rs. 5.25 crores. Paid-up capital increased to Rs. 10.91 crores.

Likely market impact

Mildly positive: revenue growth and promoter capital infusion signal confidence, but equity dilution for existing shareholders.